ONX-0801 explained

ONX-0801 (BGC 945) is an experimental drug that has been developed to target ovarian cancer.[1] It is a folate receptor alpha mediated thymidylate synthase inhibitor.[2] [3]

ONX-0801 was originally developed by BTG and the Institute of Cancer Research in the UK, and subsequently licensed to Onyx Pharmaceuticals for clinical development. It is designed to selectively target tumour tissues of certain kinds of cancer.[4] It is poorly absorbed into most cells, but is actively transported by folate receptor alpha (FRα), which is usually only expressed at low levels in the apical membrane of some specialised tissues, but is expressed at much higher levels in some subtypes of ovarian cancer. This causes the drug to accumulate selectively in tumour tissues, while healthy tissues are only exposed to a much lower concentration.[5] [6] [7]

In 2017, it received press coverage following the successful completion of a Phase I clinical trial.[8] [9] [10]

Notes and References

  1. Web site: Ovarian cancer drug delivers 'very promising' results in early trial . 3 June 2017. The Institute of Cancer Research, London. 2017-06-03.
  2. News: A Phase I trial of ONX-0801. 19 July 2013. Health Research Authority. 2017-06-03. en-US.
  3. Jarmuła A . Antifolate inhibitors of thymidylate synthase as anticancer drugs . Mini Reviews in Medicinal Chemistry . 10 . 13 . 1211–22 . November 2010 . 20854257 . 10.2174/13895575110091211 .
  4. Gibbs DD, Theti DS, Wood N, Green M, Raynaud F, Valenti M, Forster MD, Mitchell F, Bavetsias V, Henderson E, Jackman AL . BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumors . Cancer Research . 65 . 24 . 11721–8 . December 2005 . 16357184 . 10.1158/0008-5472.CAN-05-2034 . free .
  5. Ng C, et al. Efficacy and tolerability of the thymidylate synthase (TS) inhibitor, BGC 945 is mediated through its selective uptake via the α-folate receptor (α-FR) in IGROV-1 human tumor xenografts. Cancer Res May 1, 2008 (68) (9 Supplement): 3289.
  6. Book: Ng CH, Jackman AL . Potential for α-folate receptor-targeted treatment for ovarian cancer. . Emerging Therapeutic Targets in Ovarian Cancer . 2011 . 245–258 . Springer . New York, NY. .
  7. Tochowicz A, Dalziel S, Eidam O, O'Connell JD, Griner S, Finer-Moore JS, Stroud RM . Development and binding mode assessment of N-[4-[2-propyn-1-yl[(6S)-4,6,7,8-tetrahydro-2-(hydroxymethyl)-4-oxo-3H-cyclopenta[g]quinazolin-6-yl]amino]benzoyl]-l-γ-glutamyl-D-glutamic acid (BGC 945), a novel thymidylate synthase inhibitor that targets tumor cells . Journal of Medicinal Chemistry . 56 . 13 . 5446–55 . July 2013 . 23710599 . 3880649 . 10.1021/jm400490e .
  8. News: Drug shrinks ovarian tumours in early trial. Warry. Richard . vanc . 2017-06-03. BBC News. 2017-06-03. en-GB.
  9. News: Researchers hail biggest breakthrough in advanced ovarian cancer for a decade. 2017-06-02. The Independent. 2017-06-03. en-GB.
  10. Banerji U, Ingles Garces AH, Michalarea V, Ruddle R, Raynaud FI, Riisnaes R, Nava Rodrigues D, Tunariu N, Porter JC, Ward SE, Parmar M . An investigator-initiated phase I study of ONX-0801, a first-in-class alpha folate receptor targeted, small molecule thymidylate synthase inhibitor in solid tumors. . Journal of Clinical Oncology . 35 . 2017 . suppl . abstr 2503 . 10.1200/JCO.2017.35.15_suppl.2503 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "ONX-0801".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.